Generex combines AE37 with Merck ’s Keytruda in Phase II trial for TNBC

Generex Biotechnology has signed a clinical trial collaboration agreement through its Antigen Express division to combine its cancer vaccine AE37 with Merck ’s Keytruda (pembrolizumab) in a Phase II clinical trial for patients with triple-negative bre…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news